Publications

1. Baussano I, Tenet V, Baghdasarova K, Harutyunyan Z, Vorsters A, Heideman D, et al. (2025). HPV burden in Armenia among unvaccinated women: a series of cross-sectional population-based prevalence surveys. Vaccine. 62:127405. https://doi.org/10.1016/j.vaccine.2025.127405 PMID:40627870
2. Chandran A, Mackie A, Sasieni P, Arbyn M, Carvalho AL, Chauvet C, et al.; CervScreen Technical Working Group (2025). Technical, legal and ethical framework of cancer audit in cervical screening – summary of best practices for organised programmes delineated through an expert group consultation. Int J Cancer. 157(1):32–40. https://doi.org/10.1002/ijc.35403 PMID:40208390
3. Feng X, Zahed H, Onwuka J, Callister MEJ, Johansson M, Etzioni R, et al. (2024). Cancer stage compared with mortality as end points in randomized clinical trials of cancer screening: a systematic review and meta-analysis. JAMA. 331(22):1910–7. https://doi.org/10.1001/jama.2024.5814 PMID:38583868
4. Feng X, Alcala K, Guida F, Goldberg M, Zins M, Leleu O, et al. (2025). Eligibility criteria for lung cancer screening in France: a modelling study. Lancet Reg Health Eur. 51:101221. https://doi.org/10.1016/j.lanepe.2025.101221 PMID:39968190
5. Fuady A, Kasempa C, Lucas E, Nyambe N, Rao DW, Tenet V, et al. (2025). Economic evaluation of thermal ablation compared to cryotherapy and loop diathermy in a screen-and-treat approach to cervical cancer, Zambia. Bull World Health Organ. 103(9):530–40. https://doi.org/10.2471/BLT.24.292792 PMID:40900929
6. Huang Y, Georges D, Rumgay H, Soerjomataram I, Clifford GM (2025). Global burden of cancer attributable to HIV: a worldwide incidence analysis. Lancet Glob Health. 13(9):e1525–32. https://doi.org/10.1016/S2214-109X(25)00264-5 PMID:40845879
7. Joshi S, Muwonge R, Bhosale R, Chaudhari P, Kulkarni V, Mandolkar M, et al. (2025). A randomised controlled non-inferiority trial to compare the efficacy of ‘HPV screen, triage and treat’ with ‘HPV screen and treat’ approach for cervical cancer prevention among women living with HIV. Nat Commun. 16(1):1888. https://doi.org/10.1038/s41467-025-56926-3 PMID:39987163
8. Malvi SG, Esmy PO, Muwonge R, Joshi S, Poli URR, Lucas E, et al. (2024). A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination. J Natl Cancer Inst Monogr. 2024(67):317–28. https://doi.org/10.1093/jncimonographs/lgae042 PMID:39529521
9. Man I, Georges D, Basu P, Baussano I (2024). Leveraging single-dose human papillomavirus vaccination dose-efficiency to attain cervical cancer elimination in resource-constrained settings. J Natl Cancer Inst Monogr. 2024(67):400–9. https://doi.org/10.1093/jncimonographs/lgae035 PMID:39529528
10. Mosquera I, Chandran A, Rol ML, Mesmin Olivier AY, Herve Julius YB, Asnake TM, et al. (2025). Assessment of barriers to the cervical cancer continuum and existing interventions in 5 African countries. BMC Public Health. 26(1):111. https://doi.org/10.1186/s12889-025-25733-2 PMID:41345850
11. Nemati S, Dardashti AR, Mohebbi E, Kamangar F, Malekzadeh R, Zendehdel K, et al. (2024). Potential impact of controlling opium use prevalence on future cancer incidence in Iran. EClinicalMedicine. 73:102650. https://doi.org/10.1016/j.eclinm.2024.102650 PMID:38881571
12. Pahnke S, Alcala K, Bulos Salim C, Cortez Cardoso Penha R, Park HA, Mckay J, et al. (2025). Lymphocyte count and risk of chronic lymphocytic leukaemia. J Natl Cancer Inst. djaf338. https://doi.org/10.1093/jnci/djaf338 PMID:41324573
13. Palaniraja S, Taghavi K, Kataria I, Oswal K, Vani NV, Liji AA, et al. (2025). Barriers and contributions of rural community health workers in enabling cancer early detection and subsequent care in India: a qualitative study. BMC Public Health. 25(1):1527. https://doi.org/10.1186/s12889-025-22735-y PMID:40275281
14. Park JY, Georges D, Alberts CJ, Bray F, Clifford G, Baussano I (2025). Global lifetime estimates of expected and preventable gastric cancers across 185 countries. Nat Med. 31(9):3020–7. https://doi.org/10.1038/s41591-025-03793-6 PMID:40624406
15. Park JY, editor (2025). Population-based Helicobacter pylori screen-and-treat strategies for gastric cancer prevention: guidance on implementation (IARC Working Group Reports No. 12). Lyon, France: International Agency for Research on Cancer. https://publications.iarc.who.int/648
16. Ford AC, Yuan Y, Park JY, Forman D, Moayyedi P (2025). Eradication therapy to prevent gastric cancer in Helicobacter pylori-positive individuals: systematic review and meta-analysis of randomized controlled trials and observational studies. Gastroenterology. 169(2):261–76. https://doi.org/10.1053/j.gastro.2024.12.033 PMID:39824392
17. Ramírez AT, Clifford GM, Dillner J, Kuhn L, Arbyn M, Bhatla N, et al. (2025). Reflections regarding validation of new HPV tests with reduced HPV genotypes: report from an IARC expert consultation. J Med Virol. 97(3):e70310. https://doi.org/10.1002/jmv.70310 PMID:40109087
18. Selmouni F, Bendahhou K, Muwonge R, Sauvaget C, Abahssain H, Lucas E, et al. (2026). Quality of life trajectories in breast cancer survivors up to one year after treatment: a prospective study in a lower-middle-income country. Qual Life Res. 35(2):46. https://doi.org/10.1007/s11136-025-04105-8 PMID:41533246
19. Le Bonniec A, Sauvaget C, Lucas E, Nassiri A, Selmouni F (2025). Design and validation of a chatbot-based cervical cancer screening decision aid for women experiencing socioeconomic disadvantage: user-centered approach study. JMIR Cancer. 11:e70251. https://doi.org/10.2196/70251 PMID:40705442
20. Sheikh M, Domingues A, Alcala K, Langdon R, Mariosa D, Feng X, et al. (2025). Regular use of pharmaceutical opioids and subsequent risk of cancer: a prospective cohort study and Mendelian randomization analysis. EClinicalMedicine. 89:103439. https://doi.org/10.1016/j.eclinm.2025.103439 PMID:41357337